BSV acquires key brand from Jagdale Industries

Mumbai: Bharat Serums and Vaccines, a leading biopharmaceutical Company in India has acquired Tidilan® (Isoxsuprine hydrochloride), a leading brand in women’s health from Jagdale Industries, Bengaluru. Tidilan is currently available in tablet and injectable dosage forms.

BSV has some of the leading women’s health brands such as Rhoclone^®, Hucog®, Hucog 5000 HP®, AntiD^® among others.

Tidilan® (Isoxsuprine hydrochloride) is used for relaxing uterine muscles to prevent premature labour, among expecting mothers. It belongs to a class of medication called ‘vasodilator’ and is also used to treat and prevent Raynaud’s phenomenon, cerebral vascular insufficiency (arteriosclerosis), and other conditions involving poor blood flow in the blood vessel (veins and arteries).

Speaking about this, Sanjiv Navangul, Managing Director & CEO, Bharat Serums & Vaccines, said, “There exists a lot of opportunity in India to address the medical needs of women.  As a focused women’s health company, we are committed to acquiring brands that complement our current women’s portfolio.  We are delighted with the addition of Tidilan® (Isoxsuprine hydrochloride) to BSV’s Women’s Healthcare portfolio. This will be an important milestone towards our goal of being the top three women’s health players in India and as we continue to bring treatments and cures that help serve our patients better.”

Rajesh Jagdale, Chairman & Managing Director, Jagdale Industries, added, “At Juggat Pharma we are committed to delivering excellence through quality and innovation.  We are proud of our market leading brand, Tidilan® (Isoxsuprine hydrochloride) and are delighted with this partnership with BSV as we are confident that this will expand BSV’s offerings in women’s health as they work towards bringing more products that will improve lives of women in the country.”